Histofy, a leading biomedical technology company developing transparent AI solutions for pathology, announces a partnership with Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, enabling laboratories across the world to access Histofy’s cutting-edge AI tools.
Birmingham, UK (14th February 2024) – Histofy is excited to offer its AI models via the Paige AppLab™, which serves as an extensive marketplace, enabling pathologists to effortlessly browse, trial, and purchase AI tools with just a few clicks. Histofy products will be accessible from within the Paige Platform and FullFocus® viewer, widening the reach of AI in routine practice.
Nasir Rajpoot, Co-Founder, CEO & CSO of Histofy, said, “We are thrilled to announce our collaboration with Paige, a move that marks a significant milestone in our journey towards revolutionising pathology and research with our innovative AI solutions. The partnership opens a highly promising route to market for Histofy, enabling our AI products to reach a wider audience of pathologists and researchers who are already engaged with the advanced capabilities of the Paige Platform.”
"The partnership with Paige opens a highly promising route to market for Histofy, enabling our AI products to reach a wider audience"
Histofy continues to expand its range of leading AI models and will initially offer MitPro, a tool for next-generation mitosis analysis, and CoBi, a tool for AI-powered colon biopsy screening via the Paige AppLab™.
Professor Rajpoot added, “By integrating our groundbreaking AI tools with Paige’s robust platform, we are poised to bring about a transformative change in the field of pathology. With Paige’s extensive network and platform capabilities, we are confident that our AI solutions will become more accessible to healthcare professionals, ultimately contributing to better patient outcomes and advancing the field of medical research.”
Andy Moye, CEO of Paige, said “Paige is dedicated to providing pathologists with cutting-edge tools tailored for real-world clinical use. We are thrilled to partner with Histofy in advancing this mission. The inclusion of Histofy’s MitPro and CoBi tools in the Paige AppLab™ offers a straightforward mechanism for pathologists to incorporate AI into their digital pathology workflows”.
Histofy is currently working towards CE-mark under IVDR for both its MitPro and CoBi tools. To find out more, click the button below.
About Histofy
Histofy develops transparent AI solutions for computational pathology to improve the treatment of various diseases, such as cancer. With a focus on tissue-based diagnostics and prognostics, our technology complements pathologists to help deliver better patient care.
With leading research spanning over two decades, our team thoroughly understands the process of technology development, from concept to validation, placing us in prime position to bring cutting-edge AI to clinical and pharmaceutical settings.
About Paige
Paige uses the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment.
